Arcutis Biotherapeutics, Inc. · NASDAQ:ARQT

Arcutis Biotherapeutics — Technical Presentation (June 2022)

22 slides from Arcutis Biotherapeutics's technical presentation, Jun 9, 2022

  1. Slide 1: STRATUM Phase 3 Seborrheic Dermatitis Topline Data Presentation

    STRATUM Phase 3 Seborrheic Dermatitis Topline Data Presentation June 2022

  2. Slide 2: Legal Disclaimers

    2©Copyright 2022. Arcutis Biotherapeutics, Inc. All rights reserved. Presentation designed for an investor audience. Legal Disclaimers This presentation and the accompanying oral presentation contain “forward-looking” statements that are based on our management’s beliefs and assumptions and on infor

  3. Slide 3: Today's Speakers

    3©Copyright 2022. Arcutis Biotherapeutics, Inc. All rights reserved. Presentation designed for an investor audience. Today’s Speakers Frank Watanabe President & CEO Patrick Burnett, MD, PhD, FAAD Chief Medical Officer Ken Lock Chief Commercial Officer Zoe Diana Draelos, MD, FAAD Principal Investigat

  4. Slide 4: Arcutis Overview

    4©Copyright 2022. Arcutis Biotherapeutics, Inc. All rights reserved. Presentation designed for an investor audience. Arcutis Overview Speakers & Agenda

  5. Slide 5: 2022: A Transformational Year for Arcutis

    5©Copyright 2022. Arcutis Biotherapeutics, Inc. All rights reserved. Presentation designed for an investor audience. 2022: A Transformational Year for Arcutis Topical roflumilast offers a differentiated clinical profile, targeting three distinct disease areas each with >2 million topically treated p

  6. Slide 6: First of Four Potential Transformational Catalysts

    6©Copyright 2022. Arcutis Biotherapeutics, Inc. All rights reserved. Presentation designed for an investor audience. First of Four Potential Transformational Catalysts * Phase 3 topline for INTEGUMENT-1 and -2; INTEGUMENT-PED expected in 2023 Roflumilast Cream Roflumilast Foam Atopic Dermatitis Phas

  7. Slide 7: Topical Roflumilast Opportunity: ~7 Million Dermatologist-Treated Patients in the U.S. Alone

    7©Copyright 2022. Arcutis Biotherapeutics, Inc. All rights reserved. Presentation designed for an investor audience. Topical Roflumilast Opportunity: ~7 million Dermatologist-Treated Patients in the U.S. Alone Psoriasis Atopic Dermatitis Seborrheic Dermatitis Prevalence ~9M ~26M ~10M Topical Rx trea

  8. Slide 8: Topical Roflumilast – A Differentiated & Transformational Clinical Profile

    8©Copyright 2022. Arcutis Biotherapeutics, Inc. All rights reserved. Presentation designed for an investor audience. Topical Roflumilast – A Differentiated & Transformational Clinical Profile Efficacy results on par with steroid / vitamin D combinations Non-steroidal with ability to use chronically,

  9. Slide 9: Seborrheic Dermatitis Disease State Education

    9©Copyright 2022. Arcutis Biotherapeutics, Inc. All rights reserved. Presentation designed for an investor audience. Seborrheic Dermatitis Disease State Education Speakers & Agenda Zoe Diana Draelos, MD, FAAD Principal Investigator & President, Dermatology Consulting Services, PLLC

  10. Slide 10: Seborrheic Dermatitis – Significant Unmet Needs in Current Treatment Paradigm

    10©Copyright 2022. Arcutis Biotherapeutics, Inc. All rights reserved. Presentation designed for an investor audience. Seborrheic Dermatitis – Significant Unmet Needs in Current Treatment Paradigm

  11. Slide 11: Clinical Results

    11©Copyright 2022. Arcutis Biotherapeutics, Inc. All rights reserved. Presentation designed for an investor audience. Speakers & Agenda Clinical Results Zoe Diana Draelos, MD, FAAD

  12. Slide 12: STRATUM Phase 3 Trial in Seborrheic Dermatitis

    12©Copyright 2022. Arcutis Biotherapeutics, Inc. All rights reserved. Presentation designed for an investor audience. STRATUM Phase 3 Trial in Seborrheic Dermatitis IGA = Investigator’s Global Assessment; IGA Success = Clear or Almost Clear with at least a 2-grade improvement from baseline; WI-NRS:

  13. Slide 13: Rapid and Robust Results on IGA Success in Pivotal Phase 3 STRATUM Trial

    13©Copyright 2022. Arcutis Biotherapeutics, Inc. All rights reserved. Presentation designed for an investor audience. Rapid and Robust Results on IGA Success in Pivotal Phase 3 STRATUM Trial 43.2% 73.2% 80.1% 26.6% 47.9% 59.2% 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% Week 2 Week 4 Week 8 P e rc e

  14. Slide 14: Over 50% of Patients Achieved IGA of Clear at Week 8

    14©Copyright 2022. Arcutis Biotherapeutics, Inc. All rights reserved. Presentation designed for an investor audience. Over 50% of Patients Achieved IGA of Clear at Week 8 IGA = Investigator’s Global Assessment 16.4% 35.6% 50.7% 6.5% 14.9% 28.2% 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% Week 2 Week

  15. Slide 15: Robust Itch Response in Phase 3

    15©Copyright 2022. Arcutis Biotherapeutics, Inc. All rights reserved. Presentation designed for an investor audience. Robust Itch Response in Phase 3 WI-NRS: Worst Itch Numeric Rating Scale; WI-NRS response = 4 point reduction in WI-NRS in patients with WI-NRS > 4 at baseline 32.6% 47.9% 63.6% 15.6%

  16. Slide 16: Roflumilast Foam Was Well-Tolerated in Phase 3

    16©Copyright 2022. Arcutis Biotherapeutics, Inc. All rights reserved. Presentation designed for an investor audience. Roflumilast Foam Was Well-Tolerated in Phase 3 AE: adverse event; SAE: serious adverse event; TEAE: treatment-emergent adverse event Subjects (%) Roflumilast 0.3% (n=304) Vehicle (n=

  17. Slide 17: Most Common Treatment Emergent Adverse Events

    17©Copyright 2022. Arcutis Biotherapeutics, Inc. All rights reserved. Presentation designed for an investor audience. Most Common Treatment Emergent Adverse Events (>1.0% in Any Group) *All graded as mild Preferred Term Roflumilast 0.3% (n=304) Vehicle (n=153) Overall (n=457) COVID-19 11 (3.6%) 5 (3

  18. Slide 18: Commercial Opportunity

    18©Copyright 2022. Arcutis Biotherapeutics, Inc. All rights reserved. Presentation designed for an investor audience. Speakers & Agenda Commercial Opportunity

  19. Slide 19: Roflumilast Foam Could Become Standard of Care in Seborrheic Dermatitis

    19©Copyright 2022. Arcutis Biotherapeutics, Inc. All rights reserved. Presentation designed for an investor audience. Roflumilast Foam Could Become Standard of Care in Seborrheic Dermatitis Efficacy data showing meaningful symptomatic improvement The ability to use on all affected areas of the body

  20. Slide 20: Opportunity Comparable in Size to Psoriasis With No Products Promoted

    20©Copyright 2022. Arcutis Biotherapeutics, Inc. All rights reserved. Presentation designed for an investor audience. Opportunity Comparable in Size to Psoriasis With No Products Promoted 1Arcutis Quantitative Seb Derm Research August 2020, n=100 Dermatology HCPs; TRx = prescription Mild Moderate Se

  21. Slide 21: Patients Are Dissatisfied with Complex and Onerous Treatment Regimens

    21©Copyright 2022. Arcutis Biotherapeutics, Inc. All rights reserved. Presentation designed for an investor audience. Patients Are Dissatisfied with Complex and Onerous Treatment Regimens 1Harris Poll Seborrheic Dermatitis Survey (n>600 HCPs, n=300 patients), OTC = over the counter 1.4 2.1 2.4 Presc

  22. Slide 22: Thank You Q&A

    22©Copyright 2022. Arcutis Biotherapeutics, Inc. All rights reserved. Presentation designed for an investor audience. Zoe Diana Draelos, MD, FAAD Thank You Q&A

Arcutis Biotherapeutics — Technical Presentation (June 2022) on 6ix